Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy

Nature

Volumn 533, Issue 7604, 2016, Pages 547-551

  Li, Zhenfei ^a   Alyamani, Mohammad ^a   Li, Jianneng ^a   Rogacki, Kevin ^b   Abazeed, Mohamed ^b   Upadhyay, Sunil K ^c   Balk, Steven P ^d   Taplin, Mary Ellen ^d   Auchus, Richard J ^c   Sharifi, Nima ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 KETO 5ALPHA ABIRATERONE; ABIRATERONE; DRUG METABOLITE; DUTASTERIDE; ENZALUTAMIDE; MESSENGER RNA; STEROID 5ALPHA REDUCTASE 1; UNCLASSIFIED DRUG; 3-KETOABIRATERONE; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; ANTIANDROGEN; AR PROTEIN, HUMAN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANDROGEN; CANCER; DISEASE TREATMENT; DRUG; ENZYME ACTIVITY; METABOLISM; METABOLITE; SERUM; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANDROGEN THERAPY; ARTICLE; BINDING AFFINITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SYNTHESIS; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; BLOOD; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; ABIRATERONE ACETATE; ADMINISTRATION, ORAL; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENES; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; DUTASTERIDE; HUMANS; MALE; MICE; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971273444     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17954     Document Type: Article

References (32)

1. Attard, G. et al. Prostate cancer. Lancet 387, 70-82 (2016).
2. Sharifi, N. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 154, 4010-4017 (2013).
3. Li, Z. et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523, 347-351 (2015).
4. Chang, K. H. et al. A gain-of-function mutation in DHT synthesis in castrationresistant prostate cancer. Cell 154, 1074-1084 (2013).
5. Scher, H. I., Sawyers, C. L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261 (2005).
6. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
7. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
8. Chang, K. H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728-13733 (2011).
9. Russell, D. W., Wilson, J. D. Steroid 5 ?-reductase: two genes/two enzymes. Annu. Rev. Biochem. 63, 25-61 (1994).
10. Hirsch, K. S. et al. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 ?-reductase type 1. Proc. Natl Acad. Sci. USA 90, 5277-5281 (1993).
11. Clark, R. V. et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5?-reductase inhibitor. J. Clin. Endocrinol. Metab. 89, 2179-2184 (2004).
12. Rižner, T. L. et al. Human type 3 3?-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144, 2922-2932 (2003).
13. Byrne, G. C., Perry, Y. S., Winter, J. S. Steroid inhibitory effects upon human adrenal 3 ?-hydroxysteroid dehydrogenase activity. J. Clin. Endocrinol. Metab. 62, 413-418 (1986).
14. Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309-1322 (2013).
15. Attard, G. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507-516 (2012).
16. Taplin, M. E. et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J. Clin. Oncol. 32, 3705-3715 (2014).
17. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
18. Carreira, S. et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
19. Miyamoto, D. T. et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2, 995-1003 (2012).
20. Mostaghel, E. A. et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913-5925 (2011).
21. Biswas, M. G., Russell, D. W. Expression cloning and characterization of oxidative 17?-and 3?-hydroxysteroid dehydrogenases from rat and human prostate. J. Biol. Chem. 272, 15959-15966 (1997).
22. Mohler, J. L. et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 71, 1486-1496 (2011).
23. Papari-Zareei, M., Brandmaier, A., Auchus, R. J. Arginine 276 controls the directional preference of AKR1C9 (rat liver 3?-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells. Endocrinology 147, 1591-1597 (2006).
24. Li, Z. et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523, 347-351 (2015).
25. Liu, L. L. et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33, 3140-3150 (2014).
26. Hörnberg, E. et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6, e19059 (2011).
27. Deng, W., Wang, Y., Liu, Z., Cheng, H., Xue, Y. HemI: a toolkit for illustrating heatmaps. PLoS ONE 9, e111988 (2014).
28. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
29. Hänzelmann, S., Castelo, R., Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
30. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
31. Mootha, V. K. et al. PGC-1?-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267-273 (2003).
32. Alyamani, et al. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: innovation in separation of diastereoisomers without use of a chiral column. J. Steroid Biochem. Mol. Biol. http://dx.doi.org/doi:10.1016/j.jsbmb.2016.04.002 (2016).